Proliferative vitreoretinopathy Pipeline Analysis and Clinical Trials Assessment, 2025 by DelveInsight | Aldeyra Therapeutics, Tetra Bio-Pharma, Aviceda Therapeutics

Proliferative vitreoretinopathy Pipeline constitutes 3+ key companies continuously working towards developing 3+ Proliferative vitreoretinopathy treatment therapies, analyzes DelveInsight.

Proliferative vitreoretinopathy Overview:

Proliferative Vitreoretinopathy (PVR) is a rare eye condition that can result in vision loss or blindness. It typically develops after retinal detachment surgery or from an open globe injury (eye trauma). In PVR, retinal cells proliferate and form scar tissue, which then contracts and pulls the retina away. There is currently no approved treatment for PVR, which causes 75% of complications following retinal detachment and affects 5-10% of individuals who undergo retinal detachment surgery. It can also occur in up to 50% of those who experience an open globe injury.

Download our report @ https://www.delveinsight.com/report-store/proliferative-vitreoretinopathy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

"Proliferative vitreoretinopathy Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Proliferative vitreoretinopathy Therapeutics Market.

Key Takeaways from the Proliferative vitreoretinopathy Pipeline Report

DelveInsight's Proliferative vitreoretinopathy pipeline report depicts a robust space with 80+ active players working to develop 100+ pipeline therapies for Proliferative vitreoretinopathy treatment.
Aldeyra Therapeutics is advancing ADX-2191, a preservative-free, intravitreal formulation of methotrexate, for the prevention of PVR. In 2018, the FDA granted ADX-2191 Orphan Drug Designation for PVR prevention. The Phase 3 GUARD trial demonstrated that ADX-2191 was statistically superior to historical controls in preventing retinal detachment and showed numerical superiority over routine surgical care in several secondary endpoints. The drug was well-tolerated, with no serious adverse events reported. In 2023, Aldeyra planned to hold a Type C meeting with the FDA to discuss the completion of clinical development for ADX-2191 in PVR prevention.
Key Proliferative vitreoretinopathy companies such as Aldeyra Therapeutics, Tetra Bio-Pharma, Aviceda Therapeutics, and others are evaluating new drugs for Proliferative vitreoretinopathy to improve the treatment landscape.
Promising Proliferative vitreoretinopathy therapies include ADX-2191, PPP-003, and others.

Proliferative vitreoretinopathy Pipeline Analysis
The Proliferative vitreoretinopathy pipeline insights report 2025, provides insights into:
Provides comprehensive insights into key companies developing therapies in the Proliferative vitreoretinopathy Market.

Categorizes Proliferative vitreoretinopathy therapeutic companies by development stage: early, mid, and late-stage.

Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.

Reviews emerging Proliferative vitreoretinopathy drugs under development based on:

Stage of development

Proliferative vitreoretinopathy Route of administration

Target receptor

Monotherapy vs. combination therapy

Proliferative vitreoretinopathy Mechanism of action

Molecular type

Offers detailed analysis of:

Company-to-company and company-academia collaborations

Proliferative vitreoretinopathy Licensing agreements

Funding and investment activities supporting future Proliferative vitreoretinopathy market advancement.

Request for a sample report @ https://www.delveinsight.com/sample-request/proliferative-vitreoretinopathy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Proliferative vitreoretinopathy Emerging Drugs

ADX-2191: Aldeyra Therapeutics

ADX-2191, an intravitreal formulation of methotrexate, has received Orphan Drug Designation for preventing Proliferative Vitreoretinopathy (PVR). Its clinical effectiveness in PVR patients is thought to stem from the inhibition of abnormal retinal cell proliferation and activity, leading to reduced retinal scarring associated with the condition. Aldeyra holds an exclusive license for certain patents concerning the use of ADX-2191 in PVR prevention.

PPP-003: Tetra Bio-Pharma

PPP003 (HU308) has been granted Orphan Drug Designation by the U.S. Food and Drug Administration for preventing Proliferative Vitreoretinopathy.

Proliferative vitreoretinopathy Companies

Around 3 or more key companies are working on therapies for Proliferative Vitreoretinopathy. Aldeyra Therapeutics is among the companies with drug candidates for this condition in the most advanced stage, namely Phase III.

DelveInsight's report covers around 100+ products under different phases of Proliferative vitreoretinopathy clinical trials like

Proliferative vitreoretinopathy Late stage Therapies (Phase III)
Proliferative vitreoretinopathy Mid-stage Therapies (Phase II)
Proliferative vitreoretinopathy Early-stage Therapies (Phase I)
Proliferative vitreoretinopathy Pre-clinical and Proliferative vitreoretinopathy Discovery stage Therapies
Proliferative vitreoretinopathy Discontinued & Inactive Therapies

Proliferative vitreoretinopathy pipeline report provides the Proliferative vitreoretinopathy therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous
Subcutaneous
Oral
Intramuscular

Proliferative vitreoretinopathy Products have been categorized under various Molecule types such as

Monoclonal antibody
Small molecule
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Proliferative vitreoretinopathy Therapies and Key Proliferative vitreoretinopathy Companies: Proliferative vitreoretinopathy Clinical Trials and recent advancements https://www.delveinsight.com/report-store/proliferative-vitreoretinopathy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Proliferative vitreoretinopathy Pipeline Therapeutic Assessment
• Proliferative vitreoretinopathy Assessment by Product Type
• Proliferative vitreoretinopathy By Stage
• Proliferative vitreoretinopathy Assessment by Route of Administration
• Proliferative vitreoretinopathy Assessment by Molecule Type

Download Proliferative vitreoretinopathy Sample report to know in detail about the Proliferative vitreoretinopathy treatment market @ Proliferative vitreoretinopathy Therapeutic Assessment https://www.delveinsight.com/sample-request/proliferative-vitreoretinopathy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Content

1. Report Introduction
2. Executive Summary
3. Proliferative vitreoretinopathy Current Treatment Patterns
4. Proliferative vitreoretinopathy - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Proliferative vitreoretinopathy Late-Stage Products (Phase-III)
7. Proliferative vitreoretinopathy Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Proliferative vitreoretinopathy Discontinued Products
13. Proliferative vitreoretinopathy Product Profiles
14. Proliferative vitreoretinopathy Key Companies
15. Proliferative vitreoretinopathy Key Products
16. Dormant and Discontinued Products
17. Proliferative vitreoretinopathy Unmet Needs
18. Proliferative vitreoretinopathy Future Perspectives
19. Proliferative vitreoretinopathy Analyst Review
20. Appendix
21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Proliferative vitreoretinopathy Pipeline Reports Offerings: https://www.delveinsight.com/report-store/proliferative-vitreoretinopathy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.